Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Xencor, Inc.

AI spending keeps rising across chips, cloud, and next‑gen software, and a few AI-focused ETFs still offer big upside. Three funds – Invesco NASDAQ...

3 AI ETFs With 70%+ Upside to Buy in September, According to Analysts

Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. The Phase 1 trial A Phase 1 Trial, Evaluating the Safety and Tolerability ...

Xencor Advances Dual-Antibody Cancer Trial, Keeping Investor Focus on XNCR

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xencor (XNCR), Revolution Medicines (RVMD) and Roiva...

Analysts’ Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GoodRx Holdings (GDRX), Xencor (XNCR) and PepGen I...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XNCR	$26.58	-0.15%	270.73K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XNCR	$26.58	-0.2%	270.73K
3
4
5
6

XNCR

Get Xencor, Inc. Data in Excel

Get Xencor, Inc. Data in Excel